Cyclosporine disposition

EDWARDS D J, FITZSIMMONS M E, SCHUETZ E G, YASUDA K, DUCHARME M P, WARBASSE L H, WOSTER p M, SCHUETZ J D, WATKINS p (1999) 6, 7 -Dihydroxybergamottm in grapefruit juice and Seville orange juice effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 65 237-44. 

McLellan RA, Drobitch RK, McLellan H, Acott PD, Crocker JF, Renton KW. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995 58(3) 322-7. 

J. M. Kovarik, L. Vevnillet, E. A. Mueller, et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a micro-emulsion formulation. Then Drug. Monit. 16, 519-25, (1994)... 

Chowbay B, Cnmaraswamy S, Cheung Y B, et al. (2003). Genetic polymorphisms in MDRl and CYP3A4 genes in Asians and the inflnence of MDRl haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogen. 13 89-95. 

Tsunoda SM, Hanis RZ, Freeman RB, Warshaw A. Acute and chronic wine effects on cyclosporine disposition. BrJ Clin Pharmacol (2000) 42. 

Kim YH, Yoon YR, Kim YW, Shin JG, Cha IJ. Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Transplant Proc (1998) 30, 3570-2. 

Edwards D.J., M.E. Fitzsimmons, E.G. Schuetz, K. Yasuda, M.P. EXicharme, L.H. Warbasse, P.M. Woster, J.D. Schuetz, and P. Watkins. 1999. 6, 7 -Dihydroxybergamottin in grapefmit juice and Seville orange juice Effects on cyclosporine disposition, enterocyte CYP3A4, and P-gJycopiotein. Clin. Pharmacol. Ther. 65(3) 237-44. 

The use of polymeric nanoparticles in the eye has gained considerable interests in recent years. Ocular disposition, safety, efficacy, and pharmacokinetic profiles of various nanoparticles offer a wide range of application for the delivery of many drugs used to treat common ocular disorders. Polymeric nanoparticles have been utilized to enhance the performance of ibuprofen and cyclosporine, while reducing systemic side effect of carteolol compared with... 

Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995 57(5) 485 91. 

Lemaire and co-workers [167] and Lithell et al. [168] have also suggested that the disposition of cyclosporine is dictated by its lipoprotein-binding profile and that the patterns of LP association determine both its activity and toxicity. In support of these findings, several investigators have shown that the toxicity of CY may be attenuated in patients with hypertriglyceridemia (and presumably increased levels of CY in TRL) [169, 170] and enhanced in patients with hypercholesterolemia [171], Specifically, Gardier and co-workers showed an increase in LDL-associated CY in heart transplant patients with hypercholesterolemia and a concurrent increase in CY-mediated renal toxicity [172], Unfortunately, the activity of CY also appears to be enhanced when bound to LDL (and not VLDL or HDL), suggesting that increases in CY LDL may lead to increases in both therapeutic activity and toxicity [173, 174],... 

Yates C, ZhangW, Song P, Li S, Gaber A, Kotb M, Honaker MR, Alloway RR, Meibohm B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003 43 555-564. 

Westley IS, Brogan LR, Morris RG, et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites effect of cyclosporine. Drug Metab Dispos 2006 34(2) 261-266. 

Despite our inability to predict quantitatively the influence P-gp may have on the in vivo transport of substrates in normal tissues with respect to other processes, in vitro experiments remain the best means of demonstrating that a compound is a substrate for polarized efflux. Nearly all experiments designed to study the extent of P-gp efflux of test compounds in vivo require adequate in vitro data to support the hypothesis (48,217,226,454). In vitro studies on P-gp substrates such as vinblastine, paclitaxel, cyclosporin A, talinolol, acebutolol, and digoxin have provided a good indication of the effect of P-gp on the in vivo pharmacokinetic behavior of these compounds. These studies show that results from the in vitro studies provide a qualitative estimate of the influence of P-gp on its in vivo pharmacokinetic behavior. Findings such as these give confidence that results from in vitro experiments can be extrapolated to explain modulation of dmg disposition by P-gp efflux. 

Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant dmg therapy with cyclosporine A in transplant recipients. Transplant Proc 1993 25 2732-2734. 

Min DI, Lee M, Ku YM, Flanigan M. 2000. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. 68 478-86... 

Regazzi, M.B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A. and Vigano, M. (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. 

Treiber, A., Schneiter, R., Hausler, S. and Stieger, B. (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3 inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabolism and Disposition The Biological Fate of Chemicals, 35, 1400-1407. 

---